🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06896994
Recruiting Not applicable

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

NCT06896994 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Started
2025-04-01
Last updated
2025-04-27

Condition(s) studied

Postherpetic Neuralgia

Investigational drug(s) / intervention(s)

esketamine groupcontrol group

esketamine group: In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

control group: receiving the combination of pregabalin and duloxetine

Study summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Ages more than 18 years; 2. Pain present for more than 3 months after healing of a herpes zoster skin rash; 3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain); 4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy. Exclusion Criteria: 1. Obstructive sleep apnoea syndrome; 2. Those who receive interventional treatments; 3. A history of systemic immune diseases, organ transplantation, or cancers; 4. A history of severe cardiopulmonary, hepatic or renal dysfunction; 5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. Currently using monoamine oxidase inhibitors (MAOIs); 7. Having untreated angle-closure glaucoma; 8. Those suffering from increased intracranial pressure; 9. Comorbid hyperthyroidism or phaeochromocytoma; 10. Suspected or confirmed history of drug abuse; 11. Having contraindications to esketamine, pregabaline or duloxetine; 12. Communication difficulties; 13. Women who are preparing for pregnancy, in the pregnancy or lactation period.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality Recruiting

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06896994 on ClinicalTrials.gov ↗ ← All trials in China